FLAURA2 data reinforce TAGRISSO® as backbone therapy for EGFR-mutated advanced lung cancer in combination with chemotherapy; granted Breakthrough Thera...
TAE Life Sciences has announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino aci...
– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix’s Tentacles™ Platform – – Gilead Re...
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the first collaboration in the Koneksa Academic Part...
GE HealthCare’s smart phone-sized Portrait Mobile frees the patient from the hospital bed while providing continuous monitoring of vital signs, usi...
ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ is presently i...
ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the Acclaim-3...
-Imperative Care, Inc., a medical technology company elevating care for people affected by stroke and other ischemic diseases, announced a new organi...
T-SCCC will support initiatives seeking to ensure success of organ transplants for patients The PPD clinical research business of Thermo Fisher Scientific...
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the...
United Digestive now offers patients receiving a colonoscopy an enhanced screening by GI Genius™ intelligent endoscopy module. The GI Geniu...
This collaboration occurs in the wake of recent advancements from GERO, which sparked vigorous discussion among longevity experts in the scientific communi...
"Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness—even, in sever...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22...
© 2025 Biopharma Boardroom. All Rights Reserved.
